Insight Molecular Diagnostics (OCX) Live Share Price, Invest From India

Insight Molecular Diagnostics Stock Performance

as on June 18, 2025 at 6:59 am IST

$3.17
Day's Price Range
$3.17
$3.17
52 Week's Low
52 Week's High
$2.78
52-Week Price Range
$3.21
$3.17
12.30%
Downside
1.26%
Upside

Insight Molecular Diagnostics share price movements today

Previous Close: $2.73
Open: $3.17
Volume: 3.5K
Day's Low - High: $3.17 - $3.17
52 Week Low - High: $2.78 - $3.21

Insight Molecular Diagnostics Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Insight Molecular Diagnostics Stock Fundamentals & Key Indicators

Check Insight Molecular Diagnostics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

0.00

Return On Equity TTM

0.00%

Insight Molecular Diagnostics stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Insight Molecular Diagnostics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Insight Molecular Diagnostics	Buy	$-	NA	NA	0.00%	0.00%

Analyst Recommendation on Insight Molecular Diagnostics Stock

Based on 8 analysts

BUY

62.50%

Buy

37.50%

Hold

0.00%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'BUY' rating for Insight Molecular Diagnostics. Average target price of $5.42

Insight Molecular Diagnostics Share Price Target

Get share price movements and forecasts by analysts on Insight Molecular Diagnostics.

What analysts predicted

41.51%UPSIDE

Target Price

$5.42

Current Price

$3.17

Analyzed by

8 Analysts

Target

$5.42

Insight Molecular Diagnostics target price $5.42, a slight upside of 41.51% compared to current price of $3.17. According to 8 analysts rating.

Insight Molecular Diagnostics Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	0	0	0	0	0	0	0	0	1	2
Gross Profit	0	0	0	0	0	0	0	0	0	1
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-44	-45	-8	-6	-15	-9	-4	-13	-33	-6
Net Profit Margin	-16415.33%	-15264.31%	-1799.78%	-1512.59%	-5092.99%	-5186.93%	-4355.77%	-11733.04%	-2255.11%	-312.02%

Insight Molecular Diagnostics Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	0	1	7	0	1	1
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-8	-11	-19	-15	-22	-29	-64	-73	-27	-60
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-139556.25%	-2461.51%	-829.52%	-7665.97%	-1848.37%	-3225.04%

Global Institutional Holdings in Insight Molecular Diagnostics

Check out the Institutions with significant holdings in Insight Molecular Diagnostics.

Funds	Holdings
BROADWOOD CAPITAL Inc	39.87%
Awm Investment Company Inc	9.86%
BlackRock Inc	0.28%
Morgan Stanley - Brokerage Accounts	0.22%
HRT FINANCIAL LLC	0.04%

See all

About Insight Molecular Diagnostics

Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.

Organisation

Insight Molecular Diagnostics

FAQs

What is Insight Molecular Diagnostics share price today?

Insight Molecular Diagnostics share price today is $3.17 as on June 18, 2025 at 1:29 am IST at the close of the market. Insight Molecular Diagnostics share today touched a day high of $3.17 and a low of $3.17.

What is the 52 week high and 52 week low for Insight Molecular Diagnostics share?

Insight Molecular Diagnostics share touched a 52 week high of $3.21 on June 17, 2025 and a 52 week low of $2.78 on June 17, 2025. Insight Molecular Diagnostics stock price today i.e. June 18, 2025 at 1:29 am IST is closed at $3.17,which is 1.25% down from its 52 week high and 14.03% up from its 52 week low.

How to invest in Insight Molecular Diagnostics Stock (OCX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Insight Molecular Diagnostics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Insight Molecular Diagnostics Stock (OCX) from India?

Indian investors can start investing in Insight Molecular Diagnostics (OCX) shares with as little as ₹94.94999694824219 or $1 (as of November 1, 2026 at 10:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in Insight Molecular Diagnostics stock (as per the Rupee-Dollar exchange rate as on November 1, 2026 at 10:38 am IST). Based on Insight Molecular Diagnostics share’s latest price of $3.17 as on June 18, 2025 at 1:29 am IST, you will get 3.1546 shares of Insight Molecular Diagnostics. Learn more about fractional shares .